> Detailanzeige

Gruber, Leonhard [VerfasserIn]; Decristoforo, Clemens [VerfasserIn]; Uprimny, Christian [VerfasserIn]; Hohenberger, Peter [VerfasserIn]; Schönberg, Stefan [VerfasserIn]; Orlandi, Francesca [VerfasserIn]; Mariani, Maurizio Franco [VerfasserIn]; Manzl, Claudia [VerfasserIn]; Kasseroler, Maria Theresia [VerfasserIn]; Tilg, Herbert [VerfasserIn]; Zelger, Bettina [VerfasserIn]; Jaschke, Werner [VerfasserIn]; Virgolini, Irene J. [VerfasserIn]

Imaging properties and tumor targeting of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Imaging properties and tumor targeting of 68Ga-NeoBOMB1, a gastrin-releasing peptide receptor antagonist, in GIST patients
  • Beteiligte: Gruber, Leonhard [VerfasserIn]; Decristoforo, Clemens [VerfasserIn]; Uprimny, Christian [VerfasserIn]; Hohenberger, Peter [VerfasserIn]; Schönberg, Stefan [VerfasserIn]; Orlandi, Francesca [VerfasserIn]; Mariani, Maurizio Franco [VerfasserIn]; Manzl, Claudia [VerfasserIn]; Kasseroler, Maria Theresia [VerfasserIn]; Tilg, Herbert [VerfasserIn]; Zelger, Bettina [VerfasserIn]; Jaschke, Werner [VerfasserIn]; Virgolini, Irene J. [VerfasserIn]
  • Erschienen: 11 November 2022
  • Erschienen in: Biomedicines ; 10(2022), 11, Artikel-ID 2899, Seite 1-13
  • Sprache: Englisch
  • DOI: 10.3390/biomedicines10112899
  • ISSN: 2227-9059
  • Identifikator:
  • Schlagwörter: <sup>68</sup>Ga-NeoBOMB1 ; GIST ; GRPR ; PET/CT ; phase IIa study
  • Entstehung:
  • Anmerkungen: Im Titel ist die Zahl 68 hochgestellt
  • Beschreibung: Background: Gastrin-releasing peptide receptors (GRPRs) are molecular imaging targets in multiple malignancies. Recently, NeoBOMB1, a 68Ga-labelled antagonist to GRPRs, was developed for PET. Here we report the outcome of a Phase I/IIa clinical trial (EudraCT 2016-002053-38) describing diagnostic properties and covariates influencing uptake of 68Ga-NeoBOMB1 in oligometastatic gastrointestinal stromal tumor (GIST) patients. Methods: Nine patients with advanced GIST using PET/CT (computed tomography) were included. After kit-based 68Ga-NeoBOMB1 preparation with a licensed 68Ge/68Ga generator, 3 MBq/kg body weight were injected intravenously. PET/CT included dynamic and static PET scans 5, 12 and 18 min and 1, 2, and 3-4 h post injection (first six patients) and static PET scans 2 and 3-4 h post injection (last three participants). Tumor targeting was assessed on a per-lesion and per-patient basis. Results: Six patients showed visible radiotracer uptake in at least one tumor lesion. Seventeen out of 37 tumor lesions exhibited significant 68Ga-NeoBOMB1 uptake (median SUVmax 11.8 [range 2.8-51.1] 2 h p.i. and 13.2 [range 2.5-53.8] 3-4 h p.i) and improved lesion-to-background contrast over time. Five lesions (13.5%) were identified only by 68Ga-NeoBOMB1-PET, with no correlation on contrast-enhanced CT. Three patients showed no radiotracer accumulation in any lesions. Tracer uptake correlated with male sex (p < 0.0001), higher body mass index (p = 0.007), and non-necrotic lesion appearance (p = 0.018). There was no association with whole-lesion contrast enhancement, hepatic localization, mutational status, or disease duration. Conclusions: 68Ga-NeoBOMB1-PET exhibits variable tumor uptake in advanced-stage GIST patients, correlating with lesion vitality based on CT contrast uptake, opening the possibility of a theragnostic approach in selected cases.
  • Zugangsstatus: Freier Zugang